Erratum: Identification and validation of biomarkers associated with acute and chronic graft versus host disease (Bone Marrow Transplantation (2015) 50 (1563-1571) DOI: 10.1038/bmt.2015.191);Identification and validation of biomarkers associated with acute and chronic graft versus host disease

Bone Marrow Transplantation

Volumn 50, Issue 12, 2015, Pages 1563-1571

  Ahmed, S S ^a,b   Wang, X N ^a,b   Norden, J ^a   Pearce, K ^a   El Gezawy, E ^a   Atarod, S ^a   Hromadnikova, I ^c   Collin, M ^a   Holler, E ^d   Dickinson, A M ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ALCYOMICS LTD   (United Kingdom)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; CXCL11 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 33; MESSENGER RNA; CYTOKINE;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; BAFF GENE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CXCL10 GENE; CXCL11 GENE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VALIDATION STUDY; ACUTE DISEASE; ALLOGRAFT; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MULTICENTER STUDY;

ACUTE DISEASE; ALLOGRAFTS; BIOMARKERS; CHRONIC DISEASE; CYTOKINES; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE;

EID: 84949108615     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2016.125     Document Type: Erratum

References (50)

1. Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117: 3214-3219
2. Reddy P, Teshima T, Kukuruga M, Ordemann R, Liu C, Lowler K et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001; 194: 1433-1440
3. Zhang C, Todorov I, Zhang Z, Liu Y, Kandeel F, Forman S et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006; 107: 2993-3001
4. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-674
5. Miura Y, Thoburn CJ, Bright EC, Chen W, Nakao S, Hess AD. Cytokine and chemokine profiles in autologous graft-versus-host disease (GVHD): interleukin 10 and interferon gamma may be critical mediators for the development of autologous GVHD. Blood 2002; 100: 2650-2658
6. Jaksch M, Remberger M, Mattsson J. Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 280-287
7. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R et al. A biomarker panel for acute graft-versus-host disease. Blood 2009; 113: 273-278
8. Miyamoto T, Akashi K, Hayashi S, Gondo H, Murakawa M, Tanimoto K et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graftversus-host disease. Bone Marrow Transplant 1996; 17: 185-190
9. Or R, Kalinkovich A, Nagler A, Weisman Z, Naparstek E, Weiss L et al. Soluble tumor necrosis factor (sTNF) receptors: a possible prognostic marker for bone marrow transplantation-related complications. Cytokines Mol Ther 1996; 2: 243-250
10. Imamura M, Hashino S, Kobayashi H, Kubayashi S, Hirano S, Minagawa T et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versushost disease. Bone Marrow Transplant 1994; 13: 745-751
11. Levine JE, Logan BR, Wu J, Alousi AM, Bolanos-Meade J, Ferrara JL et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012; 119: 3854-3860
12. Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicenter study. Lancet Haematol 2015; 2: e21-e29
13. MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant 2015; 21: 761-767
14. Harris AC, Ferrara JL, Braun TM, Holler E, Teshima T, Levine JE et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 2012; 119: 2960-2963
15. Shin OS, Harris JB. Innate immunity and transplantation tolerance: the potential role of TLRs/NLRs in GVHD. Korean J Hematol 2011; 46: 69-79
16. Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007; 13: 6107-6114
17. Piper KP, Horlock C, Curnow SJ, Arrazi J, Nicholls S, Mahendra P et al. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graftversus-host disease in the skin following allogeneic stem-cell transplantation. Blood 2007; 110: 3827-3832
18. Croudace JE, Inman CF, Abbotts BE, Nagra S, Nunnick J, Mahendra P et al. Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD. Blood 2012; 120: 4246-4255
19. Pavletic SZ, Carter SL, Kernan NA, Henslee-Downey J, Mendizabal AM, Papadopoulos E et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005; 106: 3308-3313
20. Khan WN. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 2009; 183: 3561-3567
21. Melchers F. Actions of BAFF in B cell maturation and its effects on the development of autoimmune disease. Ann Rheum Dis 2003; 62(Suppl 2): ii25-ii27
22. Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009; 113: 3865-3874
23. Nasti TH, Timares L. Inflammasome activation of IL-1 family mediators in response to cutaneous photodamage. Photochem Photobiol 2012; 88: 1111-1125
24. Landfried K, Bataille F, Rogler G, Brenmoehl J, Kosovac K, Wolff D et al. Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versushost disease. Clin Exp Immunol 2009; 159: 87-92
25. Watson MJ, Ke B, Shen XD, Gao F, Busuttil RW, Kupiec-Weglinski JW et al. Intestinal ischemia/reperfusion injury triggers activation of innate toll-like receptor 4 and adaptive chemokine programs. Transplant Proc 2008; 40: 3339-3341
26. Zeiser R, Penack O, Holler E, Idzko M. Danger signals activating innate immunity in graft-versus-host disease. J Mol Med (Berl) 2011; 89: 833-845
27. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-832
28. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-127
29. Dickinson AM, Sviland L, Carey P, Reid MM, Hamilton PJ, Pearson AJ et al. Skin explant culture as a model for cutaneous graft-versus-host disease in humans. Bone Marrow Transplant 1988; 3: 323-329
30. Vogelsang GB, Hess AD, Berkman AW, Tutschka PJ, Farmer ER, Converse PJ et al. An in vitro predictive test for graft versus host disease in patients with genotypic HLA-identical bone marrow transplants. N Engl J Med 1985; 313: 645-650
31. Wang XN, Collin M, Sviland L, Marshall S, Jackson G, Schulz U et al. Skin explant model of human graft-versus-host disease: prediction of clinical outcome and correlation with biological risk factors. Biol Blood Marrow Transplant 2006; 12: 152-159
32. Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol 2012; 158: 30-45
33. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956
34. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc 2008; 3: 1101-1108
35. Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459-2464
36. Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers ME, Cutler CS et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011; 117: 6714-6720
37. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475-3486
38. Quartuccio L, Fabris M, Moretti M, Barone F, Bombardieri M, Rupolo M et al. Resistance to rituximab therapy and local BAFF overexpression in Sjogren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J 2008; 2: 38-43
39. Mapara MY, Leng C, Kim YM, Bronson R, Lokshin A, Luster A et al. Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR. Biol Blood Marrow Transplant 2006; 12: 623-634
40. Storek J, Ferrara S, Ku N, Giorgi JV, Champlin RE, Saxon A. B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant 1993; 12: 387-398
41. Brink R. Regulation of B cell self-tolerance by BAFF. Semin Immunol 2006; 18: 276-283
42. Reichenbach DK, Schwarze V, Matta BM, Tkachev V, Lieberknecht E, Liu Q et al. The IL-33/ST2 axis augments effector T cell responses during acute GVHD. Blood 2015; 125: 3183-3192
43. Hancock WW, Lu B, Gao W, Csizmadia V, Faia K, King JA et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000; 192: 1515-1520
44. Hancock WW, Gao W, Faia KL, Csizmadia V. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000; 12: 511-516
45. Uppaluri R, Sheehan KC, Wang L, Bui JD, Brotman JJ, Lu B et al. Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation 2008; 86: 137-147
46. Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD. Donorderived IP-10 initiates development of acute allograft rejection. J Exp Med 2001; 193: 975-980
47. Mavin E, Ahmed SS, O'Boyle G, Turner B, Douglass S, Norden J et al. Regulatory T cells inhibit CD8(+) T-cell tissue invasion in human skin graft-versus-host reactions. Transplantation 2012; 94: 456-464
48. Grenier JM, Wang L, Manji GA, Huang WJ, Al-Garawi A, Kelly R et al. Functional screening of five PYPAF family members identifies PYPAF5 as a novel regulator of NF-kappaB and caspase-1. FEBS Lett 2002; 530: 73-78
49. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA 2009; 106: 9021-9026
50. Ponce DM, Hilden P, Mumaw C, Devlin SM, Lubin M, Giralt S et al. High day 28 ST2 levels predict for acute graft-versus-host disease nd transplant-related mortality after cord blood transplantation. Blood 2014; 125: 199-205